Format

Send to

Choose Destination
Virology. 2019 Mar;529:57-64. doi: 10.1016/j.virol.2019.01.011. Epub 2019 Jan 14.

Anti-V2 antibody deficiency in individuals infected with HIV-1 in Cameroon.

Author information

1
Department of Pathology, New York University School of Medicine, New York, NY 10016, USA.
2
Medical Diagnostic Center, Yaoundé, Cameroon; Chantal Biya International Reference Center for Research on HIV/AIDS Prevention and Management, Yaoundé, Cameroon.
3
Medical Diagnostic Center, Yaoundé, Cameroon; Faculty of Science, University of Dschang, Dschang, Cameroon.
4
Veterans Affairs New York Harbor Healthcare System, New York, NY, USA.
5
Population Health, New York University School of Medicine, New York, NY, USA.
6
Molsoft, LLC, San Diego, CA, USA.
7
Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
8
Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY, USA.
9
Department of Pathology, New York University School of Medicine, New York, NY 10016, USA. Electronic address: mirek.gorny@nyumc.org.

Abstract

The results of the RV144 vaccine clinical trial showed a correlation between high level of anti-V1V2 antibodies (Abs) and a decreased risk of acquiring HIV-1 infection. This turned the focus of HIV vaccine design to the induction of elevated levels of anti-V2 Abs to increase vaccine efficacy. In plasma samples from HIV-1 infected Cameroonian individuals, we observed broad variations in levels of anti-V2 Abs, and 6 of the 79 plasma samples tested longitudinally displayed substantial deficiency of V2 Abs. Sequence analysis of the V2 region from plasma viruses and multivariate analyses of V2 characteristics showed a significant difference in several features between V2-deficient and V2-reactive plasma Abs. These results suggest that HIV vaccine immunogens containing a shorter V2 region with fewer glycosylation sites and higher electrostatic charges can be beneficial for induction of a higher level of anti-V2 Abs and thus contribute to HIV vaccine efficacy.

KEYWORDS:

HIV-1; V1V2 region; V2 antibody deficiency; V2 conformational antibodies; V2 linear antibodies

PMID:
30665098
PMCID:
PMC6512328
[Available on 2020-03-01]
DOI:
10.1016/j.virol.2019.01.011
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center